You are here

Elafin is a biomarker of graft-versus-host disease of the skin.

TitleElafin is a biomarker of graft-versus-host disease of the skin.
Publication TypeJournal Article
Year of Publication2010
AuthorsPaczesny, S, Braun, TM, Levine, JE, Hogan, J, Crawford, J, Coffing, B, Olsen, S, Choi, SW, Wang, H, Faca, V, Pitteri, S, Zhang, Q, Chin, A, Kitko, C, Mineishi, S, Yanik, G, Peres, E, Hanauer, DA, Wang, Y, Reddy, P, Hanash, S, Ferrara, JLM
JournalSci Transl Med
Volume2
Issue13
Pagination13ra2
Date Published2010 Jan 6
ISSN1946-6242
KeywordsAdolescent, Adult, Aged, Biological Markers, Child, Child, Preschool, Elafin, Enzyme-Linked Immunosorbent Assay, Graft vs Host Disease, Humans, Infant, Infant, Newborn, Middle Aged, Prognosis, Skin
Abstract

Graft-versus-host disease (GVHD), the major complication of allogeneic bone marrow transplantation, affects the skin, liver, and gastrointestinal tract. There are no plasma biomarkers specific for any acute GVHD target organ. We used a large-scale quantitative proteomic discovery procedure to identify biomarker candidates of skin GVHD and validated the lead candidate, elafin, with enzyme-linked immunosorbent assay in samples from 492 patients. Elafin was overexpressed in GVHD skin biopsies. Plasma concentrations of elafin were significantly higher at the onset of skin GVHD, correlated with the eventual maximum grade of GVHD, and were associated with a greater risk of death relative to other known risk factors (hazard ratio, 1.78). We conclude that elafin has significant diagnostic and prognostic value as a biomarker of skin GVHD.

DOI10.1126/scitranslmed.3000406
Alternate JournalSci Transl Med
PubMed ID20371463
PubMed Central IDPMC2895410
Grant ListP01 CA039542 / CA / NCI NIH HHS / United States
P01 CA039542-20 / CA / NCI NIH HHS / United States
P01-CA039542-20 / CA / NCI NIH HHS / United States
P30 CA046592 / CA / NCI NIH HHS / United States
P30 CA046592-19 / CA / NCI NIH HHS / United States
P30CA46592 / CA / NCI NIH HHS / United States
RC1 HL101102 / HL / NHLBI NIH HHS / United States
RC1 HL101102-01 / HL / NHLBI NIH HHS / United States
RC1-HL-101102 / HL / NHLBI NIH HHS / United States
People: 
David Hanauer
University of Michigan Rogel Cancer Center at North Campus Research Complex
1600 Huron Parkway, Bldg 100, Rm 1004 
Mailing Address: 2800 Plymouth Rd, NCRC 100-1004
Ann Arbor, MI 48109-2800 
Ph. (734) 764-8848 Fax. (734) 615-0507

Research reported in this publication was supported by the National Cancer Institutes of
Health under Award Number P30CA046592. The content is solely the responsibility
of the authors and does not necessarily represent the official views of the
National Institutes of Health.

Research reported in this publication was supported by the National Cancer Institutes of
Health under Award Number P30CA046592 by the use of the following Cancer Center
Shared Resource(s): Biostatistics, Analytics & Bioinformatics; Flow Cytometry;
Transgenic Animal Models; Tissue and Molecular Pathology; Structure & Drug
Screening; Cell & Tissue Imaging; Experimental Irradiation; Preclinical
Imaging & Computational Analysis; Health Communications; Immune Monitoring;
Pharmacokinetics)

Copyright © Cancer Center Informatics-2011 Regents of the University of Michigan